# Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

> **NCT00544921** · PHASE1 · COMPLETED · sponsor: **Glycadia** · enrollment: 54 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** GLY-230
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00544921
- **Lead sponsor:** Glycadia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2016-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544921, "Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00544921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*